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Abstract 
Aims: Guidelines for the management of chronic heart failure (CHF) cite the results of 
randomized controlled trials (RCTs) to support treatment recommendations. The significance 
of an observed treatment-effect relies on the use of a boundary p-value, most commonly 
p<0.05. There is concern about relying on arbitrary threshold p-values to report results as 
“statistically significant”. The “fragility index” (FI) has been proposed as an additional 
measure of the robustness of trial findings. FI is the minimum number of events needing to 
change from a non-event to an event in order to render a significant result non-significant. 
We calculated the FI to examine the robustness of statistically significant RCTs in CHF. 
 
Methods and results: Two reviewers extracted data from RCTs supporting treatment 
recommendations in CHF guidelines.  25 eligible trials were identified with a median sample 
size of 2331 patients (range 129-8399) and a median number of primary endpoints of 688.5 
(range 88-2031). For the primary endpoint (analysed for 20 trials), the median FI was 26 
(range 0-118). The FI was d10 in 7 (35%) of these 20 trials, and in 4 (20%) trials the number 
of patients lost to follow-up in the treatment group exceeded the FI. 
 
Conclusion: The results of some large RCTs in CHF hinge on a small number of events. The 
FI offers an additional, easy to understand metric, which augments the standard reporting of 
boundary p-values for statistical significance. The FI helps in the interpretation of the 
robustness of the results of RCTs. 
 
Keywords: Heart failure; Clinical trials 
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INTRODUCTION 
The practise of evidence-based medicine emphasises the importance of the results of 
randomised control trials (RCTs) in guiding and justifying treatment decisions.1 It is therefore 
crucial that such results are robust and that guideline writers and practitioners have a 
clinically meaningful and readily understandable method of evaluating robustness. Many 
clinicians, however, focus on relative risk reductions derived from hazard ratios, the 95% 
confidence intervals around these, and the threshold p-value of <0.05 which is commonly 
taken to denote statistical significance.2 However, reliance on these metrics alone is of 
concern.3 Implicit in the reporting of a relative risk reduction as “significant” is the 
assumption that a true treatment effect exists. Sample size, number of events, number of 
patients lost to follow-up, along with other factors including whether there is more than one 
trial, are also important determinants of the robustness of the findings.4,5  
 
In order to assist the interpretation of trials an additional statistical metric, the “fragility 
index” (FI), has been proposed as a tool to evaluate the robustness of results.6  FI is the 
minimum number of events that need to change from a non-event to an event in order to 
render a significant result non-significant.  The smaller the index, the more fragile the result.  
The principle underlying FI can be illustrated using an example of a trial with 100 patients 
randomised equally to treatment or placebo. If 10 patients in the treatment group experience 
an event, compared with 20 patients in the placebo group, the resultant p-value is 0.049 using 
a two-sided Fisher’s exact test. If only one more event is added to the treatment group (n=11) 
while maintaining the same event rate in the placebo group, the trial loses “significance” as 
the p-value increases to 0.083.  
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To explore the value of FI, we examined its use in assessing the robustness of the results of 
trials in chronic heart failure (HF) with reduced rejection fraction (HF-REF) as this is one of 
the most evidence-based areas in the whole of medicine.7,8 Multiple RCTs involving tens of 
thousands of patients have evaluated the effects of pharmacological and non-pharmacological 
therapies over the past thirty years. We analysed the trials providing the basis of guideline-
recommended therapy in this condition. We also tested the value of three extensions of the FI 
concept. Firstly, we examined the FI for the different regulatory p-value thresholds for 
approval of a treatment based upon two independent trials compared with one single trial. 
Secondly, we studied the impact of loss to follow-up for vital status on the fragility of results. 
Finally, we explored the concept of FI applied to the results of a group of neutral trials in HF-
REF. 
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METHODS 
We reviewed published guidelines for chronic HF-REF. We identified trials used to support 
recommendations for pharmacological or non-pharmacological treatments. We calculated the 
FI for the reported outcomes in these trials. We also explored the relationships between trial 
characteristics and the fragility of the primary outcome. 
 
Identification of studies 
We searched the electronic databases Medline and Embase using the terms “heart failure”, 
“management” and “guidelines” as title or keywords published in English after January 2010. 
Guidelines and their most recent updates from 5 international bodies were identified.7–11  
These were examined to identify RCTs used to support the treatments  in management 
algorithms for patients with HF-REF. Positive RCTs published since guideline publication 
were included by consensus of the authors. 
 
Two reviewers (KD and RC) independently reviewed all identified abstracts. Trials were 
included if they reported at least one statistically significant dichotomous primary or 
secondary outcome (p<0.05 or a 95% confidence interval that excluded the null value) and 
randomised patients to treatment or control in a 1:1 design. The FI is not suitable for use in 
situations where the ratio of intervention to control subjects is not 1:1 as altering the number 
of events in the control or intervention arm will lead to different results for the FI.6,12,13 
 
Data analysed  
Two reviewers independently screened the abstracts and full publications of included trials. 
They used a standard table to extract data from the trial and a third reviewer resolved any 
discrepancy. Data recorded included details of the primary outcome (sample size; event 
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numbers; whether outcome was composite; and number lost to follow-up). We also recorded, 
where available, the details for the following additional outcomes: all-cause mortality, 
cardiovascular mortality and HF hospitalisation. If data were not available in the primary or 
subsequent trial publications this information was then sought through correspondence with 
trial authors or from publically available Food and Drug association (FDA) documentation. 
 
FI calculation 
Using the method described by Walsh et al. FI for the statistically significant primary and 
secondary outcomes were calculated.6 We recorded the results for each outcome in a two-by-
two contingency table. We calculated the p-value for each outcome using the two-sided 
Fisher’s exact test. One event at a time was iteratively added to the group with smaller 
number of events (while subtracting one patient from the group with no events to maintain 
the total number of patients constant) and the p-value for the two-by-two table calculated. 
The FI for an outcome was the smallest number of added events required to result in a p-
value of 0.05 or greater (Supplementary Figure 1).  
 
Statistical analysis 
We report normally distributed and skewed continuous variables as means with standard 
deviations and medians with interquartile ranges (IQRs), respectively. We tested between 
group differences for significance using a Mann-Whitney U-Test for non-parametric data. 
Two-sided significance testing was used and a p value <0.05 was considered significant. All 
analyses were performed using Microsoft Excel (Microsoft, Santa Rosa, CA, USA; 2015) and 
SPSS version 22 (IBM, Chicago, IL, USA; 2013). Correlations between FI and treatment 
effect-size, sample-size and number of events were calculated using the Spearman rank test 
for non-normal data. We also calculated the FI for two value thresholds: p<0.05 (which is 
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sufficient for regulatory approval when obtained in each of two independent trials) and for 
p<0.00125 (the p value required for regulatory approval if only one trial is submitted). 
Additionally, because loss to follow-up for vital status can reduce the integrity of a trial, we 
compared FI to the number lost to follow-up. The number of patients lost to follow-up 
included, where published, the number reported as having “withdrawn consent” because, in 
many jurisdictions, this means that follow-up for vital status is not permitted. Finally, we 
extended the concept of FI to neutral trials (those with p≥0.05) of treatments not advocated in 
the treatment of HF-REF. FI was calculated by subtracting events from the investigational 
treatment group (adding non-events to this group to keep number of patients constant) and 
calculating the Fisher’s exact p-value. The FI was the number of events required to result in 
p<0.05 (in other words, the outcome resulting in the investigational treatment demonstrating 
a statistically significant benefit). 
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RESULTS 
Trial selection 
Five international guidelines on the management of chronic HF were identified and the most 
recent updates reviewed.7–11 We identified 29 trials used to support the recommendation of a 
treatment in patients with HF-REF. One trial did not require or report ejection fraction and 
two others included patients with both HF-REF and HF with preserved ejection fraction).14–16 
Among these 29 trials, 25 met the inclusion criteria (Supplementary data -Table 1).14–45 We 
excluded 4 trials because they did not allocate patients to treatment or comparator in a 1:1 
ratio.46–49 
 
Trial characteristics 
Table 1 summarises the characteristics of the 25 reviewed trials. The median sample size was 
2331 (range: 129-8399). The median follow-up in months was 25.5 (6.3-58). The number of 
trials stopped early was 8 (32%).  Of the 25 trials examined, 20 (80%) were placebo-
controlled, 3 (12%) had an active comparator design, and 2 (8%) were dose comparison 
trials. 
 
Data were available for the three additional outcomes of interest (all-cause mortality, 
cardiovascular mortality and HF hospitalisation) in 21 (84%) trials. Information for one or 
two of these additional endpoints was missing in 3 (15%) and 1 (5%) trials, respectively. 
 
The effect of the investigational treatment on the primary endpoint was significant in 23 
(92%) trials. Two trials (A-HeFT and IN-TIME) had significant composite score primary 
endpoints (non-dichotomous), meaning no FI was calculable (the dichotomous secondary 
endpoints were included in the analysis).34,44 Another trial (CHAMPION) used the primary 
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endpoint of total number of HF hospitalisations which was not suitable for calculation of the 
FI (it did however have a secondary endpoint of number of patients hospitalised with HF 
which was included).16 Therefore, we calculated FI for the primary outcome in 20 trials. The 
median number of patients with a primary outcome was 688.5 (range: 88-2031). The primary 
outcome was a composite in 11 (55%) of these trials. Reported p values for the primary 
outcome were less than 0.05 but greater than or equal to 0.01 in 4 (20%) trials, less than 0.01 
but greater than or equal to 0.001 in 7 (35%), and less than 0.001 in 9 (45%).  The effect of 
treatment on the additional endpoints of all-cause mortality, cardiovascular mortality and HF 
hospitalisation was significant in 16,16 and 18 trials respectively (not necessarily the same 
trials) and the median numbers of patients with these outcomes were 384 (range: 37-1546), 
321.5 (29-1251) and 504.5 (134-2090), respectively. 
 
Fragility index 
Tables 2 and 3 summarises FI for the examined endpoints and according to different trial 
characteristics. The median FI for the primary endpoint in the 20 trials analysed was 26 
(Interquartile range [IQR]: 8.5-39.25, range: 0-118) [Table 3]. One trial had a FI of 0 (Table 
3).45 This trial was originally significant only after adjustment for predictors of the primary 
endpoint. The FI for trials with a composite outcome and those with a single primary 
endpoint was similar. The median FI for all-cause mortality, cardiovascular mortality and HF 
hospitalisation was 13.5 (IQR: 5-33.75; range: 0-54), 9.5 (3-34;  3-34) and 38.5 (19.5-55.25;  
2-191), respectively. The FI was higher in trials stopped early (median: 37, IQR: 30-61) than 
in those not stopped prematurely (median: 17, IQR: 6-31). 
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Correlation between FI and sample-size, number of events, treatment effect-size and p-value 
FI was not significantly correlated with total sample size (R=0.312, p=0.18) or number of 
patients experiencing the primary endpoint (R=0.007, p=0.977) [Figure 1A and 1B]. There 
was no correlation between FI and the treatment/comparator hazard ratio (expressed as a 
relative risk reduction) for the primary endpoint or any of the other endpoints examined 
(Figure 2A-D).  
 
FI for p-value thresholds of <0.05 and <0.00125  
We calculated FI for p<0.05 (sufficient for regulatory approval when obtained in each of two 
separate trials) and for p<0.00125 (the p-value required for regulatory approval when a single 
trial is submitted). Of the 20 trials analysed, only 10 (50%) had a FI of >0 when considering 
the lower p-value (single trial) threshold (Table 4). The median FI for these 10 trials was 18 
(IQR: 7.5-30, range: 2-68).  
 
FI compared with number lost to follow-up for vital status 
The number of patients lost to follow-up was available for all trials and was ≥1% of total 
sample size in 7 (35%) of the 25 trials examined in which the FI was calculated for the 
primary endpoint. The total number lost to follow-up in the treatment group was the same as 
or greater than the FI for the primary endpoint in 4 (20%) trials. These trials, their respective 
number lost to follow-up in the treatment group and FI for the primary endpoint were 
HEAAL (41 and 4), SENIORS (16 and 2), SHIFT (75 and 67), and HF-ACTION (59 and 
0).15,24,36,45 
 
 
 
 11 
FI for neutral trials (p≥0.05) 
Supplementary table 2 summarises the details of 20 notable neutral trials in patients with HF-
REF where the investigational treatment was not shown to be beneficial for the primary 
endpoint (p≥0.05).50–69 The median FI for the primary endpoint was 30  (IQR: 14.75-52.25, 
range: 5-74). 
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DISCUSSION 
We examined the robustness of the results of the trials supporting treatment 
recommendations in international HF-REF guidelines. The median FI for the primary 
endpoint in these trials was 26 (i.e. on average, 26 additional events were required to change 
a result from significant to non-significant). This compares favourably with the median of 8 
found by Walsh and colleagues in their original analysis of nearly 400 trials covering a 
spectrum of medical and surgical interventions.6 Indeed, in that previous study, 25% of trials 
had a FI of d3.  
 
The lack of correlation between the treatment effect-size for the primary endpoint and FI 
illustrates how the result most practitioners focus on is an unreliable guide to the robustness 
of trial findings. Similarly, there was a lack of correlation between FI and either number of 
patients randomized or the number of patients experiencing a primary endpoint.  
 
The recently published statement by the American Statistical Association regarding p-values 
has highlighted the issues surrounding the common reliance on the use of boundary p-values 
(most commonly <0.05) to infer statistical significance and the potential size of a treatment 
effect.3 An important principle stresses is that a p-value, or statistical significance, does not 
measure the size of an effect or the importance of a result. 
 
Most clinical trials are designed on the basis of event-rates and sample sizes large enough to 
accrue an adequate number of events to provide sufficient power to allow robust assessment 
of the treatment effect. Despite this, as we have shown, the FI varies widely among trials. 
This variation reflects a number of factors including the anticipated treatment effect-size, 
event rates and the power of the study (e.g. 80% or 90%). Although early stopping for 
 13 
efficacy might in theory lead to a small FI, we found FI was actually higher in those trials, 
presumably reflecting the stringent stopping rules employed and the rarity of very early 
termination. 
 
Based on the strength, depth and breadth of evidence available, international guidelines for 
HF-REF give the strongest recommendation (i.e. class 1, level A) to five treatments: 
angiotensin-converting enzyme inhibitors (ACE-I), beta-blockers, mineralocorticoid receptor 
antagonists (MRA), implantable cardioverter-defibrillators (ICD), and cardiac 
resynchronization therapy (CRT).7–11 The three cornerstones of pharmacological therapy, 
ACE-Is, beta-blockers, and MRAs, had median FI of 8.5, 33 and 57.5, respectively, based on 
the primary endpoints in the relevant trials. However, the primary endpoint contributing to 
each of these estimates differed among trials, making direct comparison difficult. This is best 
illustrated by the two pivotal MRA trials, RALES and EMPHASIS-HF, in which FI for the 
primary endpoint was 54 and 61, respectively.32,33 However, for all-cause mortality FI was 54 
and 5, respectively (all-cause mortality was the primary endpoint in RALES whereas the 
composite of cardiovascular death or HF hospitalisation was in EMPHASIS-HF).  This 
illustrates the importance of “like-with-like” comparisons when examining endpoints across 
trials, which we believe is the most appropriate way to compare outcomes. The difference 
observed probably reflects the smaller number of deaths in EMPHASIS-HF compared with 
RALES due to the different patients enrolled, the different eras in which these two trials were 
conducted (RALES preceded use of beta-blockers and devices) and the premature 
termination of EMPHASIS-HF. Both trials, however, showed a robust treatment effect on HF 
hospitalisation (FI 41 and 49, respectively). Of course, it is also important that there are two 
large trials with a MRA in chronic HF-REF and a supporting trial in patients with left 
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ventricular systolic dysfunction (LVSD) and HF (or diabetes mellitus) after myocardial 
infarction (MI).70 
 
The relatively lower FI for ACE-Is is of interest given that these are the longest-standing 
evidence-based treatment in HF-REF. The two trials supporting the use of ACE-I, 
CONSENSUS and SOLVD-T, had a FI for the primary endpoint (all-cause mortality) of 7 
and 10, respectively.14,17 The low FI in CONSENSUS is due to few deaths, related to the 
small sample size (n=253) and premature trial termination. However, SOLVD-T was 10 
times as large and accrued 8 times as many deaths but still had a modest FI for all-cause 
mortality. The effect of enalapril on HF hospitalisation in SOLVD-T was, by comparison, 
very robust, with a FI of 91. Also, as with MRAs, any concern about robustness is further 
alleviated by having supporting trials in patients LVSD, HF or both after MI, as well as a trial 
in patients with chronic asymptomatic LVSD.71–74  
 
Of the current key pharmacological interventions, beta-blockers had the most consistent and 
robust effect on all-cause mortality with three placebo-controlled trials and one active-
controlled trial with FI of over 30 for all-cause mortality and similarly large FI for HF 
hospitalisation. One trial in much older patients, not all of which had HF-REF, did not show a 
reduction in mortality. While this difference may reflect the patients enrolled, it is also 
possible that the beta-blocker studied was less effective.75 
 
The two CRT trials with 1:1 randomization, CARE-HF and RAFT, each had a robust FI for 
the primary endpoint (40 and 23, respectively), as well as for mortality and HF 
hospitalization and are supported by two other trials without 1:1 randomization.40,41,47,48 
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The largest FI (118) for any primary endpoint was obtained in PARADIGM-HF which 
compared the angiotensin neprilysin inhibitor sacubitril/valsartan to enalapril.37  This trial 
also had one of the highest FI for all-cause mortality, at 49 (second only to RALES).  
PARADIGM-HF also highlights an extension to the basic FI metric that might be added in 
future analyses. Unlike the other drugs discussed above, there is only one trial supporting the 
use of sacubitril/valsartan. An additional measure that could be included in this situation is 
calculation of the FI not only for p<0.05 (sufficient for regulatory approval when obtained in 
each of two separate trials) but also for p<0.00125 (the p value required for regulatory 
approval if only one trial is available). Using this criterion, FI for the primary endpoint fell to 
68 in PARADIGM-HF. When the same approach was applied to SHIFT, FI also remained 
relatively robust (22).36 However, in REMATCH (a controlled trial of a first-generation left 
ventricular assist device) FI fell to 3 and in SCD-HeFT (the only trial of an ICD in patients 
with chronic HF-REF), the FI fell to zero.38,42 In other single trials, neither digoxin nor 
exercise prescription improved the primary outcome.35,45 In the trials using the combination 
of hydralazine and isosorbide dinitrate, the primary outcome was not dichotomous in one and 
the other had a FI of zero.34,46 There is also uncertainty about the robustness of the benefit of 
remote monitoring interventions.16,44 
 
Another extension of the basic FI calculation we recommend is comparison with the number 
of patients lost to follow-up for vital status.  The total number of patients lost to follow-up for 
vital status in the treatment arm was greater than FI in 4 trials. The implication of this is 
similar to the “worst case scenario” sometimes used by regulatory agencies in which all 
patients lost in the placebo group are considered alive and those lost in the active therapy 
group considered dead. As a result, even if a trial has a large FI, the results may not be as 
robust as they might seem. Take for example SHIFT, which had a FI of 67 for the primary 
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outcome, although no significant effect on cardiovascular or all-cause mortality. Assuming 
withdrawal-of-consent equated to lost to follow-up for vital status, then 75 patients in the 
ivabradine group would have missing vital status, a number considerably larger than FI.  
 
The extension of the concept of FI to neutral trials is also of interest as, in the same way, a 
large FI provides assurance about the robustness of the results i.e. that the neutral outcome is 
likely to be true rather than due to deficiencies in trial design or conduct e.g. inadequate 
power, too few events, an anticipated treatment effect that was optimistically large etc. Our 
analysis of 20 trials showed that the median FI was 30, suggesting that the majority of neutral 
trials examined can be considered to be robust. The one exception was STICH, a trial with a 
FI of 5 (the lowest of all the neutral trials) which investigated the effect of coronary-artery 
bypass grafting (CABG) in addition to medical therapy in patients with HF-REF and 
coronary artery disease.50 This means that 5 fewer deaths in the CABG arm of the trial would 
have resulted in a statistically significant result (measured by Fisher’s exact test). This may 
be a particular issue in surgical trials where there is always a small initial excess of deaths in 
the active intervention arm, with later “catch-up” if the surgery is beneficial. In keeping with 
this, the recently published 10-year extended follow-up of this trial demonstrated a 
significantly lower mortality in the CABG group compared with the medical therapy group.76 
This illustrates the potential value of extended follow-up in surgical (and potentially other) 
trials provided the number of patients lost to follow-up of vital status is kept low. 
 
Our analysis has limitations. The concept of FI can only be applied to dichotomous endpoints 
although the majority of RCTs supporting guidelines are likely to be based on dichotomous 
endpoints. Walsh et al. found no material difference in the FI between time-to-event data and 
frequency data, which they considered consistent with the concept that most results are 
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sensitive to the number of events in each group rather than the timing of the events.6 
Nevertheless, there may still be a concern about applying the FI to time-to-event data where 
the numbers of events in both groups are similar but there is a clear difference in the timing 
of the events. This could result in the inappropriate conclusion that such trials are excessively 
fragile. We have also mitigated this concern for composite time-to-event endpoints by 
calculating the FI for the individual components (all-cause mortality, cardiovascular mortality 
and HF hospitalisation) of these endpoints. We examined a moderate number of trials, 
therefore our ability to draw inference regarding the relationship between trial characteristics 
and FI is limited. Certain treatments were not as well represented as others, in particular 
devices, due to the majority of trials not using 1:1 randomisation. Because trials are powered 
to detect the presence of a treatment effect for the primary endpoint, interpretation of the 
fragility of secondary endpoints may be limited.  
 
Conclusion 
The FI offers an additional and easy to understand metric to the standard reporting of hazard 
ratios, 95% confidence intervals and boundary p-values for statistical significance in the 
interpretation of the robustness of RCTs. FI aids interpretation of the findings of randomized 
controlled trials. When applied to the evidence used to support guideline recommended 
treatments in HF-REF, we found that the significance of 7 of 20 trials (35%) rested on 10 or 
fewer events. However, the majority of treatments with the highest level of guideline 
recommendation were the more robust of the trials examined.  
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Figure Legend 
 
Figure 1A - Relationship between the fragility index and the total sample size  
 
Figure 1B - Relationship between the fragility index and the total number of primary 
outcome events 
 
 
Figure 2A - Relationship between the fragility index and the relative risk reduction 
for the primary endpoint  
 
Figure 2B - Relationship between the fragility index and the relative risk reduction 
for all-cause mortality  
 
Figure 2C - Relationship the fragility index and the relative risk reduction 
for cardiovascular mortality  
 
Figure 2D - Relationship between the fragility index and the relative risk reduction 
for heart failure hospitalisation  
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Figure 2 
 
A- Relationship between the fragility index and the relative risk reduction 
for the primary endpoint  
B - Relationship between the fragility index and the relative risk reduction 
for all-cause mortality  
C - Relationship the fragility index and the relative risk reduction 
for cardiovascular mortality 
D - Relationship between the fragility index and the relative risk reduction 
for heart failure hospitalisation  
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Table 1: Characteristics of included trials 
Trial Characteristic  Number (n= 25)* 
Sample size, median (min-max) 2331 (129-8399) 
Follow up (months), median (min-max) 25.5 (6.3-58) 
Stopped Early 8 (32) 
Placebo controlled 20 (80) 
Active comparator 3 (12) 
Dose Comparison 2 (8) 
Primary endpoint   
     Reported p-value < 0.05§ 20 (80) 
          <0.05-0.01 4 (20) 
          <0.01-0.001 7 (35) 
          <0.001 9 (45) 
     Number of outcome events, median (min-max) 688.5 (88-2031) 
     Composite outcome 11 (55) 
Secondary endpoint  
     All cause mortality  
          Reported p-value < 0.05 16 (64) 
          Number of outcome events, median (min-max) 384 (37-1546) 
     Cardiovascular mortality  
          Reported p-value < 0.05 16 (64) 
          Number of outcome events, median (min-max) 321.5 (29-1251) 
     Heart failure hospitalisation  
          Reported p-value < 0.05 18 (72) 
          Number of outcome events, median (min-max) 504.5 (134-2090) 
*  n (%) unless otherwise stated 
§ 3 trials had a significant primary endpoint but were excluded from fragility 
index analysis due to a non-dichotomous endpoint (A-HeFT and IN-
TIME34,44) and an endpoint of total heart failure hospitalisations 
(CHAMPION16) 
 
Abbreviations: min, minimum; max, maximum; n, number.  
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Table 2: Fragility index for outcomes and subgroups of trial characteristics 
Trial Characteristic 
  
Median Fragility 
Index (IQR) 
Primary endpoint (n=20) 26 (8.5-39.25) 
Composite (n=11) 23 (4-61) 
Not composite (n=9) 30 (10-35) 
Secondary endpoints  
       All-cause mortality (n=16) 13.5 (5-33.75) 
      Cardiovascular mortality (n=16) 9.5 (3-34) 
     Heart failure hospitalisation (n=18) 38.5 (19.5-55.25) 
Early stopping  
     Stopped early (n=7) 37 (30-61) 
    Not stopped early (n=13) 17 (6-31) 
Trial design  
   Placebo controlled (n=16) 25.5 (8.5-39.25) 
  Active comparator (n=3) 33  
  Dose Comparison (n=1) 4 
Sample Size  
     129-1676 (n=5) 22 (8.5-47) 
     1677-2331 (n=5) 23 (1-29.5) 
     2332-3029 (n=5) 33 (9-49) 
     3030-8399 (n=5) 34 (10.5-92.5) 
Number of primary endpoint events  
     88-383 (n=5) 30 (8.5-37) 
     384-670 (n=5) 37 (22.5-57.5) 
     671-1112 (n=5) 10 (5-31) 
     1113-2031 (n=5) 17 (2-92.5) 
 
Abbreviations: IQR, interquartile range; n, number. 
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Table 3: Fragility index for the primary and secondary outcomes 
Trial Primary Endpoint Fragility Index 
  Primary 
Endpoint 
All-
Cause 
Mortality 
CV 
Mortality 
HF 
Hospitalisation 
ACE- i      
CONSENSUS14 All cause mortality at 6 months 7* 3* 4 - 
SOLVD-Treatment17 All cause mortality 10 10 15 91 
ATLAS18,19 All cause mortality NS NS NS 21 
ARB      
Val-HeFT20,21 All cause mortality/ HF hospitalisation/ resuscitated cardiac arrest/administration of IV 
inotropic or vasodilator drugs for 4 or more hours. 
17 NS NS    59 
CHARM-Alternative22 CV death/ HF hospitalisation 29 0¶ 0¶    40 
CHARM-Added23 CV death/ HF hospitalisation 8 NS 3 5 
HEAAL24 All cause mortality/HF hospitalisation 4 NS NS 2 
² -Blockers      
CIBIS II25 All cause mortality 37 37 11 37 
MERIT-HF26,27 All cause mortality 34 34 38 50 
COPERNICUS28,29 All cause mortality 30 30 22 37 
COMET30,31 All cause mortality 33 33 43 NS 
SENIORS15 All cause mortality/ CV hospital admission 2 NS NS NS 
MRA      
RALES32 All cause mortality 54 54 46 41 
EMPHASIS-HF33 CV death/ HF hospitalisation 61 5 3 49 
H-ISDN      
A-HeFT34 Composite score - 3 2 15 
Digoxin      
DIG35 All cause mortality NS NS NS 191 
Ivabradine      
SHIFT36 CV death/ HF hospitalisation 
 
67 NS NS 91 
LCZ696      
PARADIGM-HF37 CV death/HF hospitalisation 118 49 66 54 
ICD      
SCD-HeFT38,39 All cause mortality 
 
22 22 11 - 
CRT      
CARE-HF40 All cause mortality/ hospitalisation 40 15 8 37 
RAFT41 All cause mortality/HF hospitalisation 23 12 0 24 
LVAD      
REMATCH42 All cause mortality 10 10 - - 
Home Monitoring      
CHAMPION16,43 HF hospitalisations up to six months - NS NS 4 
IN-TIME44 Worse composite score - 5 3 NS 
Exercise Training      
HF-ACTION45 All cause mortality/ hospitalisation 0¶ NS NS - 
* = Primary endpoint was all case mortality at 6 months follow up and number given for all cause mortality relates to number of deaths at the completion of the trial, ¶ = p <0.05 after adjustment, - = not reported. 
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; A-HeFT, African-American Heart Failure Trial; ARB, angiotensin receptor blocker; ATLAS, Assessment of Treatment with Lisinopril And 
Survival; CARE-HF, CArdiac REsynchronization in Heart Failure; CHAMPION, CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients; CHARM-Added, 
Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Added; CHARM-Alternative, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity - Alternative; 
CIBIS II, Cardiac Insufficiency Bisoprolol Study II; COMET, Carvedilol Or Metoprolol European Trial; CONSENSUS, COoperative North Scandinavian ENalapril SUrvival Study; COPERNICUS, Carvedilol 
Prospective Randomized Cumulative Survival Study; CRT, cardiac resynchronization therapy; CV, cardiovascular; DIG ,Digitalis Investigation Group; EMPHASIS–HF, Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart Failure; HEAAL, Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan study; HF, heart failure; HF-ACTION, Heart Failure: A 
Controlled Trial Investigating Outcomes of Exercise Training;H-ISDN, hydralazine and isosorbide dinitrate; ICD, implantable cardioverter defibrillator; IN-TIME, Influence of Home Monitoring on the Clinical 
Status of Heart Failure Patients; LVAD, left ventricular assist device; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure; MP, matching placebo; MRA, mineralocorticoid 
receptor antagonist; NS,  not significant (p ≥ 0.05); PARADIGM-HF, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial; RAFT, 
Resynchronization–defibrillation for Ambulatory heart Failure trial; RALES, Randomized Aldactone Evaluation Study; REMATCH, Randomized Evaluation of Mechanical Assistance for the Treatment of 
Congestive Heart failure; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial; SENIORS, Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure; 
SHIFT, Systolic Heart failure treatment with the If inhibitor ivabradine Trial; SOLVD –Treatment, Studies of Left ventricular dysfunction- treatment; Val-HeFT, Valsartan Heart Failure Trial. 
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Table 4: Fragility index for the primary outcome at the statistical  
boundaries of p<0.05 and p<0.00125 
Trial Fragility Index 
  p<0.05 p<0.00125 
ACE- i   
CONSENSUS 7 0 
SOLVD Treatment 10 0 
ARB 
 
 
Val-HeFT 17 0 
CHARM Alternative 29 2 
CHARM Added 8 0 
HEAAL 4 0 
² -Blockers 
 
 
CIBIS II 37 14 
MERIT HF 34 11 
COPERNICUS 30 9 
COMET 33 0 
SENIORS 2 0 
MRA 
 
 
RALES 54 29 
EMPHASIS HF 61 33 
Ivabradine 
 
 
SHIFT 67 22 
LCZ696   
PARADIGM HF 118 68 
ICD 
 
 
SCD-HeFT 22 0 
CRT 
 
 
CARE HF 40 22 
RAFT 23 0 
LVAD   
REMATCH 10 3 
Exercise Training   
HF-ACTION 0¶ 0 
¶ = p <0.05 after adjustment. 
Abbreviations as in Table 3. 
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Table 1: Chronic heart failure randomised controlled trials included in analysis 
Trial n Follow up 
(months) 
Mean/ 
Median* 
Treatment A 
 
 
 
(n) 
Treatment B 
 
 
 
(n) 
Primary Endpoint 
 
 
Primary 
Endpoint 
 A 
 
n (%) 
Primary 
Endpoint 
B 
 
n (%) 
All Cause 
Mortality 
A 
 
n (%) 
All Cause 
Mortality 
B 
 
n (%) 
CV 
Mortality 
A 
 
n (%) 
CV 
Mortality 
B 
 
n (%) 
HF 
Hospitalisation 
A 
 
n (%) 
HF 
Hospitalisation 
B 
 
n (%) 
LTFU 
A 
 
 
n (%) 
LTFU  
B 
 
 
n (%) 
Stopped 
Early 
ACE-I                 
CONSENSUS1 253 6.3 Enalapril 
(127) 
MP 
(126) 
All cause mortality at 6 
months 
33  
(26) 
55  
(44) 
50#  
(39) 
68# 
(54) 
49  
(39) 
68  
(54) 
- - 0  
(0.0) 
0 
(0.0) 
Yes 
SOLVD-Treatment2 2569 41.4 Enalapril 
(1285) 
MP 
(1284) 
All cause mortality 452  
(35) 
510  
(40) 
452  
(35) 
510  
(40) 
399  
(31) 
461  
(36) 
332  
(26) 
470  
(37) 
1  
(0.1) 
1  
(0.1) 
No 
ATLAS3,4 3164 45.7* High dose 
lisinopril 
(1568) 
Low dose 
lisinopril 
(1596) 
All cause mortality 666  
(42) 
714  
(45) 
666  
(42) 
714  
(45) 
583  
(37) 
641  
(40) 
526  
(34) 
611  
(38) 
0  
(0.0) 
0 
(0.0) 
No 
ARB                 
Val-HeFT5,6 5010 23 Valsartan 
(2511) 
MP 
(2499) 
All cause mortality/ HF 
hospitalisation/ resuscitated 
cardiac arrest/administration 
of IV inotropic or 
vasodilator drugs for 4 or 
more hours. 
723  
(29) 
801  
(32) 
495  
(20) 
484  
(19) 
427  
(17) 
419  
(17) 
346  
(14) 
455  
(18) 
3 
(0.1) 
4 
(0.1) 
No 
CHARM-
Alternative7 
2028 33.7* Candesartan 
(1013) 
MP 
(1015) 
CV death/ HF 
hospitalisation 
334  
(33) 
406  
(40) 
265  
(26) 
296  
(29) 
219  
(22) 
 
252  
(25)  
207  
(20) 
286  
(28) 
2  
(0.2) 
1  
(0.1) 
No 
CHARM-Added8 2548 41* Candesartan 
(1276) 
MP 
(1272) 
CV death/ HF 
hospitalisation 
483  
(38) 
538  
(42) 
377  
(30) 
412  
(32) 
302  
(24) 
  
347  
(27)  
309  
(24) 
356  
(28) 
3  
(0.2) 
1  
(0.1) 
No 
HEAAL9 3834 56.4* High dose 
losartan 
(1921) 
Low dose 
losartan 
(1913) 
All cause mortality/HF 
hospitalisation 
828  
(43) 
889  
(46) 
635  
(33) 
665  
(35) 
448  
(23) 
478  
(25) 
450  
(23) 
503  
(26) 
41 
(2.1) 
54 
(2.8) 
No 
² -Blockers                 
CIBIS II10 2647 16 Bisoprolol 
(1327) 
MP 
(1320) 
All cause mortality 156  
(12) 
228  
(17) 
156  
(12) 
228  
(17) 
119  
(9) 
161  
(12) 
159  
(12) 
232  
(18) 
5  
(0.4)  
1  
(0.1) 
Yes 
MERIT-HF11,12 
 
 
3991 12 Metoprolol 
CR/XL  
(1990) 
MP 
(2001) 
All cause mortality 145  
(7) 
217  
(11) 
145  
(7) 
217  
(11) 
128  
(6) 
203  
(10) 
200  
(10) 
294  
(15) 
0  
(0)  
0  
(0)  
Yes 
COPERNICUS 
13,14 
2289 10.4 Carvedilol 
(1156) 
MP 
(1133) 
All cause mortality 130 
(11) 
190  
(17) 
130  
(11) 
190  
(17) 
116  
(10) 
166  
(15) 
198  
(17) 
268  
(24) 
0  
(0)  
0  
(0)  
Yes 
COMET15,16 3029 58 Carvedilol 
(1511) 
Metoprolol 
Tartrate 
(1518) 
All cause mortality 512  
(34) 
600  
(40) 
512  
(34) 
600  
(40) 
438  
(29) 
534  
(35) 
473  
(31) 
481  
(32) 
13§ (0.9) 20§ 
(1.3) 
No 
SENIORS17 2128 21 Nebivilol 
(1067) 
MP 
(1061) 
All cause mortality/ CV 
hospital admission 
332  
(31) 
375  
(35) 
169  
(16) 
192  
(18) 
123  
(12) 
145  
(14) 
145  
(14) 
144  
(14) 
16  
(1.5)  
21  
(2.0)  
No 
MRA                 
RALES18 1663 24 Spironolactone 
(822) 
MP 
(841) 
All cause mortality 284  
(35) 
386  
(46) 
284  
(35) 
386  
(46) 
246  
(30) 
338  
(40) 
215  
(26) 
300  
(36) 
0  
(0)  
0  
(0)  
Yes 
EMPHASIS-HF19 2737 21* Eplerenone 
(1364) 
MP  
(1373) 
CV death/ HF 
hospitalisation 
249 
(18) 
356  
(26) 
171  
(13) 
213  
(16) 
147  
(11) 
185 
(13) 
164  
(12) 
253  
(18) 
17  
(1.2)  
15  
(1.0)  
Yes 
H-ISDN                 
A-HeFT20 1050 10 H-ISDN 
(518) 
MP 
(532) 
Composite score - - 32  
(6) 
54  
(10) 
26  
(5) 
45  
(8) 
85  
(16) 
130  
(24) 
0 
(0) 
0 
(0) 
Yes 
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Digoxin                 
DIG21 6800 37 Digoxin 
(3397) 
MP 
(3403) 
All cause mortality 1181  
(35) 
1194  
(35) 
1181  
(35) 
1194  
(35) 
1016  
(30) 
1004  
(30) 
910 
(27) 
1180  
(35) 
47  
(1.4) 
46  
(1.4) 
No 
Ivabradine                 
SHIFT22 6505 22.9* Ivabradine 
(3241) 
MP 
(3264) 
CV death/ HF 
hospitalisation 
 
793  
(24) 
937  
(29) 
503  
(16) 
552  
(17) 
449  
(14) 
491  
(15) 
514  
(16) 
672  
(21) 
75§  
(2.3) 
59§ 
(1.8) 
No 
LCZ696                 
PARADIGM-HF23 8399 27* LCZ696 
(4187) 
Enalapril 
(4212) 
CV death/HF hospitalisation 914  
(22) 
1117  
(27) 
711  
(17) 
835  
(20) 
558  
(13) 
693  
(16) 
537  
(13) 
658  
(16) 
11  
(0.3) 
9  
(0.2) 
Yes 
ICD                 
SCD-HeFT24,25 1676 45.5* ICD 
(829) 
UC 
(847) 
All cause mortality 
 
182  
(22) 
244  
(29) 
182  
(22) 
244  
(29) 
133  
(16) 
179  
(21) 
- - 0 
 (0) 
0  
(0) 
No 
CRT                 
CARE-HF26 813 29.4 CRT 
(409) 
UC 
(404) 
All cause mortality/ 
hospitalisation 
159  
(39) 
224  
(55) 
82  
(20) 
120  
(30) 
57  
(14) 
86  
(21) 
72  
(18) 
133  
(33) 
0  
(0) 
0  
(0) 
No 
RAFT27 1798 40 CRT-D 
(894) 
ICD 
(904) 
All cause mortality/HF 
hospitalisation 
297  
(33) 
364  
(40) 
186  
(21) 
236  
(26) 
130  
(15) 
162  
(18) 
174  
(19) 
236  
(16) 
10§  
(0.6) 
5§  
(0.6) 
No 
LVAD                 
REMATCH28 129 - LVAD 
(68) 
UC 
(61) 
All cause mortality 41  
(60) 
54  
(89) 
41  
(60) 
54  
(89) 
- - - - 0 
(0) 
2§ 
(3.3) 
No 
Home Monitoring                 
CHAMPION29,30 550 15 Device On 
(270) 
MP 
(280) 
HF hospitalisations up to six 
months 
83  
(31) 
120  
(43) 
47  
(17) 
52  
(19) 
40  
(15) 
39  
(14) 
54  
(20) 
80  
(29) 
3§ 
(1.1) 
4§ 
(1.4) 
No 
IN-TIME31 664 335(A)/ 
326(B) 
Days 
Telemonitoring 
(333) 
UC 
(331) 
Worse composite score 63   
(19) 
90  
(27) 
10  
(3) 
27  
(8) 
8  
(2) 
21  
(6) 
27  
(8) 
34  
(10) 
10§ 
(3.0) 
13§ 
(13.9) 
No 
Exercise Training                 
HF-ACTION32 2331 30* Exercise 
Training  
(1159) 
UC 
(1172) 
All cause mortality/ 
hospitalisation 
759 
(65) 
796  
(68) 
189  
(16) 
198  
(17) 
131  
(11) 
143  
(12) 
- - 59§  
(5.1) 
63§ 
(5.4) 
No 
*= Median, # = All cause mortality at end of trial follow up § = Includes withdrawal of consent, ¶ = p <0.05 after adjustment, - = not reported 
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; A-HeFT, African-American HEart Failure Trial; ARB, angiotensin receptor blocker; ATLAS, Assessment of Treatment with Lisinopril And Survival; CARE-HF, CArdiac REsynchronization in Heart Failure; 
CHAMPION, CardioMEMS Heart sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients; CHARM-Added, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity-Added; CHARM-Alternative, Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity - Alternative; CIBIS II, Cardiac Insufficiency BIsoprolol Study II; COMET, Carvedilol Or Metoprolol European Trial; CONSENSUS, COoperative North Scandinavian ENalapril SUrvival Study; COPERNICUS, Carvedilol 
Prospective Randomized Cumulative Survival Study; CRT, cardiac resynchronization therapy; CV, cardiovascular; DIG, Digitalis Investigation Group; EMPHASIS–HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; HEAAL, Heart failure Endpoint 
evaluation of Angiotensin II Antagonist Losartan study; HF, heart failure; HF-ACTION, Heart Failure: A Controlled Trial Investigating Outcomes of exercise traiNing;H-ISDN, hydralazine and isosorbide dinitrate; ICD, implantable cardioverter defibrillator; IN-TIME, Influence of 
Home Monitoring on the Clinical Status of Heart Failure Patients; LTFU, lost to follow up; LVAD, left ventricular assist device; MERIT-HF, MEtoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure; MP; matching placebo; MRA; mineralocorticoid receptor 
antagonist; PARADIGM-HF; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial; RAFT, Resynchronization–defibrillation for Ambulatory heart Failure Trial; RALES, Randomized Aldactone Evaluation Study; 
REMATCH, Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial; SENIORS, Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart 
Failure; SHIFT, Systolic Heart failure treatment with the If inhibitor ivabradine Trial; SOLVD –Treatment, Studies Of Left Ventricular Dysfunction- treatment; UC, usual care; Val-HeFT, VALsartan Heart Failure Trial. 
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Table 2: Fragility index of neutral trials 
Trial n Treatment A 
 
 
 
(n) 
Treatment 
B 
 
 
(n) 
Primary Outcome Event 
treatment 
A 
 
n (%) 
Event 
treatment 
B 
 
n (%) 
Stopped 
early 
Fragility 
index 
 
STICH33 1212 
UC + CABG 
(610) 
UC 
(602) 
All cause mortality 218 (36) 244 (41) No 5 
OVERTURE34 5770 
Omapatrilat 
(2886) 
Enalapril 
(2884) 
All cause mortality/HF 
hospitalisation 
914 (32) 973 (34) No 11 
BEST35 2708 
Bucindolol 
(1354) 
MP 
(1354) 
All cause mortality 411 (30) 449 (33) No 11 
STAT-CHF36 674 
Amiodarone 
(336) 
MP 
(338) 
All cause mortality 131 (39) 143 (42) No 14 
PRAISE I37 1153 
Amlodipine 
(571) 
MP 
(582) 
All cause mortality/CV 
hospitalisation 
222 (39) 246 (42) No 14 
ACCLAIM38 2426 
Immunomodulation 
(1213) 
MP 
(1213) 
All cause mortality/CV 
hospitalisation 
399 (33) 429 (35) No 17 
CORONA39 5011 
Rosuvastatin 
(2514) 
MP 
(2497) 
CV death/MI/Stroke 692 (28) 732 (29) No 19 
ATMOSPHERE40 4676 
Aliskiren + Enalapril 
(2340) 
Enalapril 
(2336) 
CV death/ HF 
hospitalisation 
770 (33) 808 (35) No 25 
ANDROMEDA41 627 
Dronederone 
(310) 
MP 
(317) 
All cause mortality/ HF 
hospitalisation 
53 (17) 40 (12) Yes 29 
DIAMOND-HF42 1518 
Dofetilide 
(762) 
MP 
(756) 
All cause mortality 311 (41) 317 (42) No 30 
WARCEF43 2305 
Warfarin 
(1142) 
Aspirin 
(1163) 
All cause mortality/ 
Ischaemic stroke/ICH 
302 (26) 320 (28) No 30 
ESSENTIAL44 1854 
Enoximone 
(926) 
MP 
(928) 
All cause mortality/CV 
hospitalisation 
458 (49) 465(50) No 37 
ECHO-CRT45 809 
CRT on 
(404) 
CRT off 
(405) 
All cause Mortality/ HF 
hospitalisation 
116 (29) 102 (25) Yes 39 
AF-CHF46 1376 
Rhythm Control 
(682) 
Rate 
Control 
(694) 
CV Death 182 (27) 175 (25) No 41 
FIRST47 471 
Epoprostenol 
(237) 
UC 
(234) 
All cause mortality 114 (48)  87 (37) Yes 47 
PRAISE II48 1654 
Amlodipine 
(827) 
MP 
(827) 
All Cause Mortality 
 
278 (34) 262 (32) No 54 
ECHOS49 1000 
Nolomirole 
(501) 
MP 
(499) 
All cause mortality/ HF 
Hospitalisation 
233 (47) 208 (42) No 56 
RED-HF50 2278 
Darbopoetin 
(1136) 
MP 
(1142) 
 All cause mortality/ HF 
Hospitalisation 
576 (51) 565 (49) No 61 
MACH I51 2590 
Mibefradil 
(1295) 
MP 
(1295) 
All cause mortality 350 (27) 319 (25) No 74 
GISSI-HF 
Rousvastatin52 
4574 
Rosuvastatin 
(2285) 
MP 
(2289) 
All cause mortality 657 (29) 644 (28) No 74 
Abbreviations; ACCLAIM, Advanced Chronic heart failure CLinical Assessment of IMmunomodulation; AF-CHF, Atrial Fibrillation and Congestive Heart 
Failure; ANDROMEDA, ANtiarrhythmic trial with DROnedarone in Moderate to severe CHF Evaluating morbidity DecreAse; ATMOSPHERE, The 
Aliskiren Trial to Minimize OutcomeS in Patients with HEart FailuRE; BEST, Beta-blocker Evaluation of Survival Trial; CORONA, COntrolled 
ROsuvastatin multiNAtional Trial in Heart Failure; CRT, Cardiac Resynchronization Therapy; CV, CardioVascular; DIAMOND–HF, Danish Investigations 
of Arrhythmia and Mortality ON Dofetilide; ECHO-CRT, ECHOcardiography guided Cardiac Resynchronization Therapy; ECHOS, EchoCardiography and 
Heart Outcome Study; ESSENTIAL, The Studies of Oral Enoximone Therapy in Advanced Heart Failure; FIRST, The Flolan International Randomized 
Survival Trial; GISSI-HF rosuvastatin, Gruppo Italiano per lo Studio della Sopravvivenza nell’Insuffi cienza cardiaca Heart Failure trial rosuvastatin; HF, 
Heart Failure; ICH, IntraCranial Haemorrhage; MACH I, Mortality Assessment in Congestive Heart Failure Trial; MOXCON, MOXonidine CONgestive 
heart failure trial; MP, Matching Placebo; OVERTURE, the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events; PRAISE I, 
Prospective Randomized Amlodipine Survival Evaluation; PRAISE II, Prospective Randomized Amlodipine Survival Evaluation II; PRIME II, Prospective 
Randomised study of Ibopamine on Mortality and Efficacy II; RED-HF, Reduction of Events by Darbepoetin alfa in heart failure; SERVE-HF, Adaptive 
SERvo-VEntilation for central sleep apnea in systolic Heart Failure; STAT-CHF, Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure; 
STICH, Surgical Treatment for Ischemic Heart Failure; UC, Usual Care; WARCEF, Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction. 
 
Figure 1 
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Trial Result 
 Event No Event 
Treatment A (Investigational) a b 
Treatment B (Comparator) c d 
Fisher’s Exact Test p<0.05 
 
Fragility Index Calculation 
 Event No Event 
Treatment A (Investigational) a + f b - f 
Treatment B (Comparator) c d 
Fisher’s Exact Test p≥0.05 
 
 
Fragility index calculation – One event at a time is iteratively added to the group with smaller 
number of events (while subtracting one patient from the group with no events to maintain the 
total number of patients constant). The smallest number of events, “f”, resulting in a Fisher’s 
exact p-value ≥0.05 is the fragility index. Trials with a higher fragility index are more robust.  
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